38,818 Shares in Fulgent Genetics, Inc. (NASDAQ:FLGT) Bought by Diametric Capital LP

Diametric Capital LP bought a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 38,818 shares of the company's stock, valued at approximately $717,000. Diametric Capital LP owned approximately 0.13% of Fulgent Genetics as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. JPMorgan Chase & Co. grew its stake in Fulgent Genetics by 39.4% in the 4th quarter. JPMorgan Chase & Co. now owns 471,259 shares of the company's stock valued at $8,704,000 after purchasing an additional 133,215 shares during the period. EntryPoint Capital LLC grew its position in Fulgent Genetics by 85.2% during the fourth quarter. EntryPoint Capital LLC now owns 20,771 shares of the company's stock valued at $384,000 after buying an additional 9,556 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Fulgent Genetics in the fourth quarter worth about $57,000. American Century Companies Inc. raised its position in Fulgent Genetics by 10.3% in the fourth quarter. American Century Companies Inc. now owns 45,645 shares of the company's stock worth $843,000 after acquiring an additional 4,262 shares during the period. Finally, Quantbot Technologies LP boosted its stake in Fulgent Genetics by 131.9% in the fourth quarter. Quantbot Technologies LP now owns 10,420 shares of the company's stock valued at $192,000 after acquiring an additional 5,926 shares during the last quarter. 48.06% of the stock is owned by hedge funds and other institutional investors.

Fulgent Genetics Trading Down 0.8 %

Shares of NASDAQ FLGT traded down $0.14 during midday trading on Friday, hitting $16.86. The company's stock had a trading volume of 419,744 shares, compared to its average volume of 248,490. Fulgent Genetics, Inc. has a one year low of $14.57 and a one year high of $25.11. The firm has a market capitalization of $520.40 million, a price-to-earnings ratio of -3.05 and a beta of 1.54. The stock has a fifty day moving average price of $16.80 and a 200 day moving average price of $18.49.

Remove Ads

Analyst Ratings Changes

FLGT has been the topic of a number of research reports. StockNews.com raised shares of Fulgent Genetics from a "sell" rating to a "hold" rating in a report on Wednesday, March 5th. Piper Sandler lowered their target price on Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th.

Insiders Place Their Bets

In related news, CFO Paul Kim purchased 100,000 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were purchased at an average cost of $15.96 per share, for a total transaction of $1,596,000.00. Following the completion of the transaction, the chief financial officer now directly owns 348,282 shares in the company, valued at approximately $5,558,580.72. This represents a 40.28 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 32.66% of the company's stock.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.